Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Hereditary Sensory and Autonomic Neuropathies 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

Oxaliplatin 6Gemcitabine 6Cisplatin 4durvalumab 3pembrolizumab 2Leucovorin 2Drug Therapy 2130-nm albumin-bound paclitaxel 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1sintilimab 1pertuzumab 1fludarabine 1atezolizumab 1anlotinib 1Trastuzumab 1Standard of Care 1Observation 1Nivolumab 1Neoadjuvant Therapy 1Long-Term Synaptic Depression 1Irinotecan 1Folfox protocol 1Fluorouracil 1Everolimus 1Cyclophosphamide 1Commerce 1Cholangiopancreatography, Endoscopic Retrograde 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Gallbladder Neoplasms × tivozanib × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡